March 4, 2021

Santhera Announces Completion of First 6-Month Period of VISION-DMD Trial with Vamorolone in Duchenne

Santhera Pharmaceuticals has reached an important milestone in the VISION-DMD study of vamorolone in people with Duchenne, conducted by partner ReveraGen Biopharma Inc. The company today announced that it has completed the last visit of…

Learn More

February 1, 2021

Santhera Shares Community Update on Phase 2b Trial for Vamorolone

Santhera Pharmaceuticals has shared an update with the community regarding the phase 2b trial for vamorolone, which the company expects to have data from in the second quarter of 2021. The update includes contact information…

Learn More

November 17, 2020

ReveraGen Receives $3.3 Million NIH Grant for NDA Preparations for Vamorolone in Duchenne

The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) has awarded a $3.3 million grant to ReveraGen Inc. to support the advancement of vamorolone towards FDA submission and…

Learn More

October 28, 2020

WATCH: Catabasis Phase 3 PolarisDMD Trial Results (Webinar Recording)

We were disheartened to learn earlier this week that the results from the Catabasis Phase 3 trial for edasalonexent (PolarisDMD) did not meet its primary or secondary endpoints. On October 27, 2020, PPMD was joined by…

Learn More

October 26, 2020

Catabasis Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne

We are disheartened to learn today the results from the Catabasis Phase 3 trial for edasalonexent (PolarisDMD) did not meet its primary or secondary endpoints. The unfortunate results from the Catabasis study is yet another…

Learn More

October 6, 2020

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne

Today, we are disappointed to learn that Santhera announced its decision to discontinue development of its Phase 3 SIDEROS study with Puldysa® (idebenone) in Duchenne. Santhera will stop the SIDEROS trial (including extension) and participants…

Learn More

October 2, 2020

Catabasis Shares October 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter which includes information from their presentations at the Congress of the World Muscle Society. The Phase 3 PolarisDMD trial and GalaxyDMD open-label extension trial…

Learn More

September 28, 2020

Catabasis Presents Information On Edasalonexent At 25th International Congress Of The World Muscle Society

Catabasis Pharmaceuticals today shared information on the edasalonexent program in Phase 3 development for Duchenne in poster presentations at the Virtual 25th International Congress of the World Muscle Society. The posters include new preclinical research…

Learn More

September 23, 2020

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Santhera announced a new publication in the journal PLOS Medicine describing new open-label, long-term clinical data on the safety, tolerability and efficacy…

Learn More

September 18, 2020

Catabasis Shares September 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter.  Their plan is to share top-line results from the Phase 3 PolarisDMD trial of edasalonexent with the Duchenne community later this year. As highlighted in…

Learn More